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ABSTRACT: We have developed a novel, all-electronic biosensor for opioids that consists of an 
engineered mu opioid receptor protein, with high binding affinity for opioids, chemically bonded 
to a graphene field-effect transistor to read out ligand binding. A variant of the receptor protein 
that provided chemical recognition was computationally redesigned to enhance its solubility and 
stability in an aqueous environment. A shadow mask process was developed to fabricate arrays of 
hundreds of graphene transistors with average mobility of ~1500 cm2 V-1 s-1 and yield exceeding 
98%. The biosensor exhibits high sensitivity and selectivity for the target naltrexone, an opioid 
receptor antagonist, with a detection limit of 10 pg/mL. 
 
 
 
Graphene field effect transistors (GFETs) hold tremendous promise for use as biosensor 
transduction elements due to their high carrier mobility and low noise.1, 2 There is a need for 
scalable, reproducible fabrication of GFET arrays that maintain the high graphene mobility, which 
can be significantly degraded3-6 due to contamination by conventional lithographic processing.7, 8 
It is also desirable to develop approaches where a biological chemical recognition element, e.g., a 
transmembrane G-protein coupled receptor, is redesigned for optimized integration with 
nanotechnology while retaining the protein’s native structure, sensitivity and selectivity. We 
developed a class of opioid biosensors that integrates high quality GFETs for transduction of 
ligand binding with a computationally designed water-soluble variant of the human mu-opioid 
receptor that marries functionality of the parent membrane protein with superior properties for 
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production and handling. The fabrication method is scalable with high yield, and sensors exhibit 
high sensitivity and specificity for the target. The approach is applicable to a variety of engineered 
proteins. The work represents progress toward enhanced methodologies for detection of small 
molecules at pg/mL concentrations, precise monitoring of administration of such molecules, and 
high-throughput testing of the affinities of pharmaceutical compounds for proteins of interest with 
direct electronic read out. 
 
Large-area graphene grown by chemical vapor deposition (CVD) is appropriate for scalable 
integration of graphene devices. Care must be taken to avoid lithographic contaminants, which 
strongly influence sensor responses.9 To this end, GFET fabrication was based on an approach 
where graphene is patterned during the transfer process rather than by post-transfer 
photolithography. Figure 1a is a schematic of the process. Gold lines separated by ~ 150 μm-wide 
parallel strips were deposited through a mechanical mask onto a graphene layer on its copper 
growth substrate (Fig. 1b). When a “bubbling” method transfer10 was performed, graphene covered 
by gold remained pinned on the copper foil, while uncovered regions were transferred onto an 
oxidized Si wafer with pre-fabricated source and drain contacts (Fig. 1c). Though limited to 
graphene “ribbon” widths greater than ~100 μm, the process enabled parallel fabrication of 
hundreds of GFETs, with excellent reproducibility. To quantify GFET quality, hundreds of devices 
were fabricated and characterized by electrical transport and Raman spectroscopy. The average 
mobility, μ, and Dirac voltage, VD, for 212 devices were μ = 1496 cm2 V-1 s-1 ± 567 cm2 V-1 s-1 
and VD = 15.0 V ± 5.3 V (Fig. 2b-c). Raman spectroscopy of GFET channels (Fig. S1 of the 
Supporting Information) revealed D/G intensity ratio less than 0.03, indicative of a low defect 
density, and 2D/G intensity ratio of ~1.5, typical of monolayer graphene.11 
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Figure 1. Fabrication process for high quality graphene field effect transistors (GFETs). a, Schematic of the fabrication 
process (see Methods and main text for description). b, Copper foil shadow mask placed in contact with graphene on 
catalytic copper foil. Narrow regions of graphene protected by the mask are eventually transferred onto source and 
drain contacts to form the transistor channel. c, Example of a GFET device made by transferring graphene stripes onto 
pre-fabricated electrodes, and photograph of an array of 192 GFET devices, with ~ 99.5% device yield.   
 
 
50 µm 
Source Drain 
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b 
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Figure 2. Performance characteristics of graphene field effect transistors (GFETs). a, Representative set of 
50 I-Vg curves, demonstrating the uniformity of the electrical characteristics. b, c Histograms of GFET 
mobility and Dirac voltage, along with Gaussian fits (black curves). 
a 
b 
c 
 6 
G protein-coupled receptors (GPCRs) are a family of transmembrane proteins involved in 
activating intracellular signal transduction pathways.12 GPCRs bind a variety of target ligands, 
from small molecules to large proteins. They are involved in the transmission pathways of 
numerous diseases and are the target of more than 40% of modern pharmaceuticals.13 The μ opioid 
receptor (MUR) is a GPCR involved in pain and reward signaling pathways with high binding 
affinities for opioids, e.g., β-endorphin, heroin, morphine, hydrocodone, and fentanyl.14 Generally, 
GPCRs are unstable when removed from their hydrophobic membrane environment, resulting in 
denaturation, loss of functionality, and aggregation. Moreover, high-yield heterologous expression 
and efficient purification of GPCRs remains challenging. Exterior amino acid residues of GPCRs 
in the transmembrane region are largely hydrophobic, which can impede expression and isolation. 
By computationally redesigning these residues to be hydrophilic, GPCRs and other membrane 
proteins can be identified that are expressed in large quantity in E. coli, are structurally stable 
outside of a membrane, and exhibit functionally related properties.15-19 A designed, water-soluble 
variant of human MUR can be expressed in E. coli and retains opioid affinities comparable to the 
wild type receptor.19 No membranes or membrane surrogates are required. The combination of 
these advances in obtaining functional forms of receptor proteins (GPCRs) that can be manipulated 
outside biomembranes and the GFET fabrication procedure outlined above opens a route to highly 
sensitive nanosensors, where the recognition element is essentially the biological receptor protein.  
In this work, we demonstrated a bioelectronic GFET nanosensor based on a solubilized MUR 
variant, and we used it to detect naltrexone, an opioid receptor antagonist, at concentrations as low 
as 10 pg/mL with excellent specificity. The graphene functionalization scheme presented here can 
be readily applied to other proteins; the work reveals a new family of biosensors that combine the 
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functional properties of GPCRs with the environmental sensitivity of graphene for tailored and 
targeted chemical detection.      
GFET arrays of were functionalized with water-soluble MUR using a methodology based on our 
earlier experiments with exfoliated graphene.20 To our knowledge, this is the first application of 
this approach to devices based on large-area graphene. The process began with incubation in a 
solution of 4-carboxybenzene diazonium tetrafluoroborate, which produces carboxylic acid sites 
on the graphene that were then activated and stabilized with 1-ethyl-3-[3-dimethylaminopropyl] 
carbodiimide hydrochloride /sulfo-N hydroxysuccinimide (EDC/s-NHS) in MES buffer. 
Incubation in a buffer with the water-soluble MUR led to covalent attachment of the designed 
MUR and the graphene (see Methods for further details). To measure the sensor response, a 
solution containing a known concentration of naltrexone in buffer was delivered to the sensor and 
allowed to react for 40 min before being rinsed with DI water and blown dry.  
Devices were characterized through the functionalization process by Raman spectroscopy of the 
GFET channel and Atomic Force Microscopy (AFM). Raman spectra of GFETs after incubation 
in diazonium salt solution (Fig. 3a) displayed strong increases in the D (“disorder”) peak ca. 1360 
cm-1, consistent with formation of sp3 hybridized sites.21 AFM showed enhanced binding of water-
soluble MUR to the graphene sheet compared to the SiO2 substrate and verified the effectiveness 
of the attachment chemistry, e.g. 128 proteins bound to 27 µm2 of graphene (4.7/µm2) and 5 
protein-sized features in an area of 9 µm2 of substrate (0.55/µm2) in Fig. 3b. AFM line scans were 
used to create a height histogram for immobilized proteins (Fig. 3c), which showed a primary 
maximum at ~ 4 nm, consistent with the 46 kDa mass and structure of MUR;22 secondary maxima 
at 8 and 12 nm were attributed to protein aggregates. To check that proteins were bound to the 
graphene covalently rather than by non-specific adsorption, the functionalization procedure was 
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performed with the diazonium salt step omitted. In this experiment, the density of non-specifically 
adsorbed protein on both the graphene and the oxidized silicon substrate was similar to that 
observed on the bare substrate in Fig 3b (Fig S2 of the Supporting Information). 
 
Figure 3. Results of characterization by Raman spectroscopy and Atomic Force Microscopy (AFM). a, Raman 
spectrum of graphene before (red data) and after (black data) exposure to diazonium salt solution. The strongly 
enhanced D-band (near 1360 cm-1) after diazonium treatment indicates the formation of carboxy-benzene sites on the 
graphene surface. b, AFM image of soluble mu receptor proteins (white dots) decorating the graphene surface. The 
density of protein molecules is approximately 10 times greater on the graphene as compared to the SiO2 substrate. 
Scale bar is 2 µm. c, Histogram of the heights of proteins indicating that the 46 kDa mu receptor monomer is ~4 nm 
tall on the surface, with dimers and trimers  of 8 nm and 12 nm respectively.   
b 
a 
c 
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Samples were characterized after each step of functionalization chemistry and exposure to 
naltrexone target by measuring the source-drain current as a function of back gate voltage (I-VG 
characteristic). The Dirac voltage and carrier mobility were very sensitive to chemical treatment 
(Fig. 4a). After diazonium treatment, VD increased by 70-90 V, consistent with the presence of 
negative charge (carboxylate) near the GFET channel.23 Additionally, mobility was found to be 
reduced by ~50%, which was ascribed to carrier scattering by sp3-hybridized sites created on the 
graphene surface. EDC/s-NHS treatment decreased the Dirac voltage by ~20 V, likely due to 
neutralization of carboxylate by the s-NHS ester. While MUR attachment did not significantly 
shift the Dirac point, there was an increase in the device mobility of ~10%.  
 
 For naltrexone response experiments, each device was exposed to a single concentration to 
avoid sample contamination across trials; 15-30 devices were tested against each concentration. A 
reproducible, concentration-dependent increase in VD was observed (Fig. 4e). Device-to-device 
scatter in this signal parameter appeared to be random and uncorrelated with other device 
properties, i.e., the Dirac voltage and carrier mobility. The data are well fit by a model adapted 
from the Hill-Langmuir equation that describes equilibrium binding of a ligand by a receptor.24 
The model includes a term that reflects naltrexone binding and an offset parameter Z to account 
for ΔVD observed in the absence of naltrexone: 
DVD = A
c /Ka( )
n
1+ c /Ka( )
n
+ Z
 
 
Here A is the maximum response with all binding sites occupied, c the concentration of the 
applied naltrexone solution, Ka an effective dissociation constant that describes the naltrexone 
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concentration that produces half occupation of mu receptors, n the Hill coefficient, and Z the offset 
parameter. The best fit to the data yielded values A = 9.26 ± 0.24 V, Ka = 7.8 ± 1.6 ng/mL, n = 
0.41 ± 0.03, and Z = 0.11 ± 0.03 V. During the curve fitting process, A was constrained to be in 
the range of 8.5 – 10 V based on observed responses, and the other parameters were unconstrained. 
The best fit value of the offset parameter Z = 0.11 ± 0.03 V agrees with measured responses of 
devices exposed to pure buffer (Z = 0.04 ± 0.38 V). The best fit value of Ka = 7.8 ± 1.6 ng/mL for 
the soluble MUR is within the expected range 1.5 – 100 nM, as reported previously for both the 
designed and wild-type MUR.19, 25 Under the reasonable, but not yet tested, assumption of a linear 
relationship between GFET sensor response and analyte binding, the best fit value n = 0.41 ± 0.03 
suggests negative cooperativity in the binding of naltrexone to the GFET biosensor that may be 
due to protein-protein interactions upon binding or increased charge carrier scattering with 
increased ligand binding. Similar behavior (n < 1) was observed in biosensors based on protein-
functionalized carbon nanotube transistors.26 These results demonstrate that a collection of 15-30 
GFET devices functionalized with the water soluble MUR can distinguish between pure buffer 
(ΔVD = 0.04 ± 0.38 V) and a solution containing naltrexone at a concentration of 10 pg/mL (3 pM; 
ΔVD = 0.93 ± 0.34 V).    
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Figure 4. Current-gate voltage (I-VG) characteristic measurements after chemical treatment and naltrexone exposure. 
a, I-VG plots after successive functionalization steps. After functionalization with the solubilized mu receptor, 
exposure to a solution of 1 µg/mL naltrexone in buffer leads to an increase in the Dirac voltage of 8.5 V (green curve 
a b 
c d 
e 
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to orange curve). b Magnified view of the Dirac voltage increase. c I-VG plots after successive functionalization steps 
with the device now exposed to a solution of 100 pg/mL naltrexone in buffer (green curve to orange curve). The Dirac 
voltage increase is 1.8 V. d Magnified view of this shift in the Dirac voltage. e Sensor response (increase in Dirac 
voltage) as a function of Naltrexone concentration. The signal is still discernable from the bare buffer response at 10 
pg/mL naltrexone. The data are fit to a modified Hill-Langmuir equation (black curve; see main text for details). The 
buffer response (green line) is defined as the average response plus one standard error of 15 GFETs exposed to pure 
buffer without protein. 
 
 Control experiments were conducted on 12-20 GFET devices per condition to verify that 
sensor responses reflected specific binding of naltrexone to the soluble MUR. Results are 
summarized in Table 1. Devices functionalized with water-soluble MUR were exposed to pure 
buffer with no naltrexone; the sensor response was consistent with zero (ΔVD = 0.04 ± 0.38 V). A 
benzodiazepine receptor antagonist compound, Flumazenil, at a concentration of 10 µg/mL was 
delivered to the sensors under conditions identical to the naltrexone experiments. Flumazenil is 
known not to bind to mu receptors,27 and indeed we did not observe a statistically significant shift 
in the Dirac voltage (ΔVD = -0.23 ± 0.43 V). Experiments were performed where i) the mu receptor 
addition step was omitted, and ii) where the mu receptor was replaced with an antibody fragment, 
anti-HER2 scFv. Sensor responses were measured upon exposure to naltrexone at 10 µg/mL, the 
highest concentration tested. Again, the response was consistent with zero, implying that the MUR 
was necessary to bind naltrexone and produce the characteristic ΔVD. These experiments provide 
strong evidence that sensor responses derived from specific interactions between the water-soluble 
MUR and the opioid receptor antagonist naltrexone. 
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Table 1. Summary of control experiments performed to test the conclusion that sensor responses 
derive from specific binding of naltrexone to the mu receptor protein. Quoted errors are the 
standard error of the mean. 
Sample Analyte Average Dirac Voltage Shift (V) 
MUR-GFET Buffer with no Naltrexone 0.04 ± 0.38 
MUR-GFET Flumazenil at 10 µg/mL -0.23 ± 0.43 
MUR omitted Naltrexone at 10 µg/mL -0.25 ± 0.35 
anti-HER2 scfv-GFET Naltrexone at 10 µg/mL -0.31 ± 0.48 
MUR-GFET Naltrexone at 10 µg/mL 8.78 ± 0.55 
 
 
The proposed mechanism for the concentration-dependent ΔVD is a conformational change in 
the variant MUR upon naltrexone binding, as observed for other GPCRs,28 which alters the 
electrostatic environment of the GFET (“chemical gating”). A similar chemical gating response 
has been demonstrated in carbon nanotube FETs.23 The Raman spectra of GFETs were also 
sensitive to the presence and concentration of naltrexone, (Figs. S3-4 and Table S1-2 in the 
Supporting Information), consistent with the fact that Raman spectra are also sensitive to chemical 
gating.29, 30 Although a precise quantitative understanding of the mechanism remains to be 
developed, we believe that the methods presented here could be generalized to create a new 
generation of manufacturable graphene-based biosensors with the highly sensitive and specific 
chemical recognition characteristic of GPCRs.  
In conclusion, we demonstrated a novel biosensor based on arrays of graphene FETs 
functionalized with a designed, water-soluble mu receptor protein. Scalable fabrication methods 
were used to produce large arrays of high quality graphene transistors as evidenced by electronic 
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and Raman characterization. The devices enabled detection of the opioid receptor antagonist 
naltrexone at concentrations as low as 10 pg/mL. Measured sensor responses over a range of 6 
orders of magnitude in concentration (10 pg/mL to 10 µg/mL) were well fit by a model based on 
Hill-Langmuir binding equation. Control experiments verified that the sensor response derived 
from specific binding of the mu receptor to naltrexone, indicating that the water-soluble MUR 
maintains its biologically active analyte binding configuration while covalently bound to graphene. 
By functionalizing such GFET arrays with multiple selected proteins, it should be possible to 
create a single integrated biosensor platform for detection of a large number of analytes. 
Nanoelectronic interrogation of proteins while they are subjected to new pharmaceutical 
treatments could perhaps serve as a sensitive readout for drug discovery applications. 
 
Methods 
Growth of large-area graphene by chemical vapor deposition (CVD). Continuous 
(monolayer) graphene sheets were grown on copper foil by atmospheric pressure CVD according 
to methods we published previously.31 Briefly, copper foil (Alfa Aesar Item #46365) was placed 
in a CVD tube furnace and heated to 1057°C under argon and hydrogen forming gas. Immediately 
upon reaching 1057°C, methane was introduced to the furnace chamber, and the graphene growth 
proceeded for 30 min. The furnace was then slid downstream while holding the quartz tube fixed 
so that the copper foil was outside the furnace heating elements, enabling rapid cooling of the 
copper foil necessary for monolayer graphene formation. Once the chamber cooled to 100°C, the 
foil was removed from the furnace. 
Fabrication of GFETs by patterned transfer. After graphene synthesis, the copper growth 
substrate was placed into close contact with a stripe-patterned mechanical mask and inserted into 
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a thermal evaporator (Fig. 1a). 7 nm Ti/55 nm Au were deposited on the sample, with the shadow 
mask creating parallel strips of graphene that were not covered by metal (see Fig. S1 in the 
Supporting Information). Polymethylmethacrylate (PMMA) was then spun over the surface of the 
copper foil/graphene/gold sample and baked at 100°C for 2 min. Graphene was then separated 
from the copper foil using the electrochemical “bubble” transfer method. The sample was slowly 
lowered into a 0.1 M NaOH solution with a 25 V potential difference applied between the copper 
foil and the solution. Gas bubbles formed at each electrode, which served to separate the graphene 
from the copper foil. However, graphene areas covered by gold were pinned to the copper foil, and 
only the uncovered areas were free to come off with the PMMA support layer. This approach 
enable the transfer of patterned stripes of graphene without the need for conventional 
photolithography and without introducing any additional chemicals which may cause unwanted 
doping or contamination. The PMMA/graphene layer was carefully transferred to 2 deionized 
water baths and then placed onto a Si wafer (300 nm oxide) so that it aligned with pre-fabricated 
electrodes for source and drain contacts. The PMMA was rinsed off with acetone and the devices 
were annealed in Ar/H2 for 1 hour at 200°C to remove remaining PMMA. Device yield at this 
stage typically exceeded 99%, with excellent uniformity.  
Water soluble human MUR engineering, expression and purification. A variant of water 
soluble MUR was computationally designed as described previously, wherein exterior, 
transmembrane residues were targeted and redesigned.19 The engineered variant was expressed 
and purified as described previously without further modification.19 Briefly, the synthetic cDNA 
encodings of the water soluble MUR were produced by GenScript Inc. (Piscataway, NJ). The 
sequences were subcloned between the NdeI and XhoI restriction sites of the expression plasmid 
pET-28b(+) (EMD/Novagen). This cloning strategy resulted in placement of a His-tag at the amino 
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terminus of the protein. E. coli BL21(DE3) cells (EMD/Novagen) were used for expression. The 
protein was purified using the His-tag and confirmed using mass spectrometry. 
Protein functionalization of GFETs and exposure to naltrexone target. The first step was 
incubation at 55°C in a solution of a carboxylated diazonium salt, 4-carboxybenzene diazonium 
tetrafluoroborate (2.0 mg/ mL in DI water). Diazonium salts were synthesized in house according 
to a published protocol.32 Carboxylic acid groups from the diazonium functionalization were 
activated and stabilized with 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride 
/sulfo-N hydroxysuccinimide (EDC/s-NHS) at an EDC concentration of 9 mg/15 mL MES buffer 
and NHS concentration of 20 mg/15 mL MES buffer. NHS molecules were displaced by amine 
groups on the designed MUR protein (3 µg/mL) in buffer (40µM NaPi/ 260µM NaCl / 0.00004% 
SDS/ 10µM 2-ME / pH 7.0) to form a covalent amide bond between the soluble MUR and the 
graphene. Finally, an amount of a known opioid receptor antagonist (naltrexone) was delivered to 
the sensor and allowed to react in a humid environment for 40 min before being rinsed in DI water 
and blown dry under nitrogen. The time of 40 min was chosen based on a calculation that 15 min 
would be required for diffusion of naltrexone molecules to the sensor surface and to ensure a 
binding equilibrium was established at the lowest concentrations tested. 
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